Anti-arrhythmic agents

Bibliography

• KATZ AM: The arrhythmias L Introduction: SA node, impaired conduction, AV block, unidirectional block. In: Physiology of the Heart. Raven Press, New York (1977) 293–314.
   Google Scholar
• RANADE VV, WOLF ME, MOSNAIM A: Developments in antiarrhythmic drugs: an overview. Exp. Opin. Invest Drugs (1995) 4(10:1101–1128.
   Google Scholar
• THE CARDIAC ARRHYTHMIA TRIALS SUPRESSION TRIALS (CAST) INVESTIGATORS: Preliminary report: effect of encainimide and flecanide on mortalityin a random-ized trial of arrhythmia suppression after myocardial infarction. New Eng. J. Med. (1989) 321:406–412.
   PubMedGoogle Scholar
• LAZZARA R: From first class to third class: recent up-heaval in antiarrhythmic therapy- lessons from clinical trials. Am. J. Cardiol (1996) 78(4A):28–33.
   Google Scholar
• COLATSKY TJ, ARGENTIERI TM: Potassium channel blockers as antiarrhythmic agents. Drug Dev. Res. (1994) 33:235–249.
   Google Scholar
• A symposium: a new age in the pharmacologic therapyof cardiac arrhythrnias. Singh BN, Lazzara R (Eds.), Am. J. Cardiol (1996) 78(4A).
   Google Scholar
• Acute treatment of atrial fibrillation and flutter: ibu-tilide in perspective. Waldo AL, Pratt CM (Eds.), Am. J. Cardiol (1996) 78(8A).
   Google Scholar
• SINGH BN: Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. Am. J. Cardiol. (1996) 78(4A):41–53.
   Google Scholar
• BASHIR Y, THOMSEN P-E, KINGMA JH eta].: Electrophysi-°logic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Am. J. CardioL (1995) 76(14):1040–4.
   Google Scholar
• SEDGWICK ML, DALRYMPLE I, RAE AP, COBBE SM: Effects of the new class HI antiarrhythmic drug dofetilide on the atrial and ventricular intracardiac monophasic ac-tion potential in patients with angina pectoris. Eur. Heart J. (1995) 16(10:1641–6.
   PubMedGoogle Scholar
• Scrip (1994) 25:1985.
   Google Scholar
• RASMUSSEN HS, ALLEN MJ, BLACKBURN GS, BUTROUS GS, DALRYMPLE HW: Dofetilide, a novel class III antiar-rhythmic agent. J. Cardiovasc. Pharmacol. 20:S96–S105.
   Google Scholar
• NACCARELLI VG, LEE KS, GOIBSON JK, VANDERLUGT J: Electrophysiology and pharmacology of ibutilide. Am. Cardiol (1996) 78:12–16.
   PubMedGoogle Scholar
• WALDO AL, PRATT CM: Introduction: acute treatment ofatrial fibrillation and flutter- ibutilide in perspective. Am.j Cardiol (1996) 78(8A):1–3.
   Google Scholar
• HSU C-Y, WALTERS RR: Pharmacokinetics of ibutalide and its enantiomers in dogs. ChiraliW (1996) 8(1):18–23.
   PubMedGoogle Scholar
• LYNCH JJ, Jr., WALLACE AA, STUPIENSKI RF III et al.: Cardiac electrophysiologic and antiarrhythmic actions of two long-acting spirobenzopyran pip eridine class III agents, L-702,958 and L-706,000 [MK-499]. J. Pharmacol Exp. Ther. (1994) 269(2):541–54.
   Google Scholar
• LYNCH JJ, Jr., WALLACE AA, STUMP GL et al: Differential efficacy of the class III agent MK-499 against pro-grammed stimulation-induced and ischemic-induced ventricular arrhythmias in a canine model of previous myocardial infarction. J. Pharmacol Exp. Ther. (1996) 277 (2):671–678.
   PubMedGoogle Scholar
• SANGUINETTI MC, JURKIEWICZ NK: Two components of cardiac delayed rectifier potassium current. Differen-tial sensitivity to block by class HI antiarrhythmic agents. J. Gen. Physiol. (1990) 96:195–215.
   Google Scholar
• SANGUINETTI MC, CURRAN ME, ZOU A eta].: Co-assembly of KvLQT1 and minK (IsIO proteins to form cardiac IKs potassium channel. Nature (1996) 384:80–83.
   Google Scholar
• SALATA JJ, JURKIEWICZ NK, SANGUINETTI MC et al.: The novel class of antiarrhythmic agent L-735,821 is a po-tential and selective blacker of Ls in guinea pig ven-tricular myocytes. Circulation (1996) 94:3095. Abstract 1529.
   Google Scholar
• KOMORI S, LI B, TAMURA K, HASHIMOTO K: 1K-inde-pendent class Ill actions of MS-551 compared with sematilide and dofetilide during reperfusion in anes-thetized rats. Br. J. Pharmacol. (1996) 119:937–942.
   PubMedGoogle Scholar
• ISHII M, KAMIYA J, HASHIMOTO K: Cellular electrophysi-ologicaleffects of MS-551, a new class Ill antiarrhythmic agent. Drug Dev. Res. (1995) 35:61–68.
   Google Scholar
• KOIDL B, FLASCHBERGER P, SCHAFFER P et al: Effects of the Class III antiarrhythmic drug ambasilide on out-ward currents in human atrial myocytes. Naunyn-Schiedeberg's Arch. Pharmacol. (1996) 353:226–232.
   PubMed Web of Science ®Google Scholar
• WANG J, FENG J, NATTEL S: Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide. Circulation (1994) 90:2032–2040.
   Google Scholar
• KLINIL M, KORTH M, SCHREIECK J eta].:Differe ntial class III antiarrhythmic effects of ambasilide and dofetilide at different extracellular potassium and pacing fre-quencies. J. Cardio. Pharmacol (1996) 28:314–320.
   Google Scholar
• RUSS U, ENGLERT H, SCHOLKENS BA, GOCELEIN H: Simultaneous recording of ATP-se ns itive K current and intracellular Ca2+ in anoxic rat ventricular myocytes. Effects of glibenclamide. Pflugers Arch.-Eur j Physiol (1996) 432:75–80.
   PubMedGoogle Scholar
• JOHNSON RE, SILVER PJ, BECKER R eta].: 4,5-Dihydro-3-(methanesulfonamidopheny0-1-pheny1-1H,2,4-benz odiazepines: a novel class III antiarrhythmic agents. J. Med. Chem. (1995) 38:2551–2556.
   Google Scholar
• PharmaProjects (1996) C1B a280.
   Google Scholar
• BRIL A, GOUT B, BONHOMME M et al.: Combined potas-sium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872. J. Pharmacol Exp. Ther. (1966) 276(2):637–46.
   Google Scholar
• CHARLIER R, DELTOUR G, BAUDINE A, CHAILLET F: Phar-macology of amiodarone, an antianginal drug with a new biological profile. Arzneim.-Forsch. (1968)18:1408–17.
   PubMed Web of Science ®Google Scholar
• CHATELAIN P, MEYSMANS L, MATTEAZZI JR, BEAUFORTPH, CLINET M: Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the b-adrenoceptor and adenylate cyclase in rat heart. Br. J. Pharmacol. (1995) 116(3):1949–56.
   PubMedGoogle Scholar
• Scrip (1993) 14:1871.
   Google Scholar
• Scrip (1994) 14:1888.
   Google Scholar
• RAATIKAINEN MJP, NAPOLITANO CA, DRUZGALA P, DEN-NIS DM: Electrophysiological effects of a novel, short-acting and potent ester derivative of amiodarone, ATI-2001, in guinea pig isolated heart." Pharmacol Exp. Ther. (1996) 277(3):1454–1463.
   Google Scholar
• DUFF HJ: Clinical and in vivo antiarrhythmic potential of sodium-hydrogen exchange inhibitors. Cardiovasc. Res. (1995) 29:189–193.
   PubMedGoogle Scholar
• HENDRIKX M, MUBAGWA K, VERDONCK F et al.: New Na+-11+ exchange inhibitor HOE 694 improves postis-chemic function and high-energy phosphate resynthe-sis and reduces Ca+2 overload in isolated perfused rabbit heart. Circulation (1994) 89:2787–2798.
   PubMed Web of Science ®Google Scholar
• YASUTAKE M, IBUKI C, HEARSE DJ, AVKIRAN M: Nat/It exchange and rep effusion arrhythmias: protection by intracoronary infusion of a novel inhibitor. Am. J. Physiol. (1994) 267:H2430.
   Google Scholar
• SCHOLZ W, ALBUS U, COUNILLON L et al.: Protective effects of H0E642, a selective sodium-hydrogen ex-change subtype 1 inhibitor, on cardiac ischaemia and reper fusion. Cardiovasc. Res. (1995) 29:260–268.
   PubMed Web of Science ®Google Scholar
• PharmaProjects (1996) C1B a283.
   Google Scholar
• BELARDINELLI L, PELLEG A: Rationale for the use of adenosine in the diagnosis and treatment of cardiac arrhythmias. In: Purines Cell. Signaling: Targets NewDrugs. Jacobson KA, Daley JW, Manganiello V (Eds.) Springer, New York (1990) 95–99.
   Google Scholar
• LERMANN BB, WESLEY RC, BELARDINELLI L: Electra-physiological effects of dipyridamole on atrioventricu-lar nodal conduction and supraventricular tachycardia: role of endogenous adenosine. Circulation (1989) 80:1536–1543.
   PubMedGoogle Scholar
• CONTI JB, CURTIS AB, UTTERBACK D, BELARDINELLI L: Endogenous adenosine in an antiarrhythmic agent. Circulation (1994) 91:1761–1769).
   Google Scholar
• BELARDINELLI L, PELLEG A: Cardiac electrophysiology and pharmacology of adenosine. J. Cardiovasc. Electro-physiol. (1990) 1:327–329.
   Google Scholar
• DOWNEY JM, LIU G-S, COHEN MV: Do adenosine A3 receptors cause preconditioning? Dev. Cardiovasc. Med. (1996) 181:447–458.
   Google Scholar
• LEONE RJ, FRIEDRICH GS, MERRILL GF: Adenosine deami-nase and BW a1433U attenuate hypoxia-induced ven-tricular ectopy. j Appl. Physiol. (1993) 74:1543–1548).
   PubMedGoogle Scholar
• PharmaProjects (1996) Cl-B.
   Google Scholar